Cwm LLC cut its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 57.2% during the first quarter, Holdings Channel.com reports. The fund owned 6,279 shares of the biotechnology company's stock after selling 8,389 shares during the period. Cwm LLC's holdings in Axon Enterprise were worth $865,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of AXON. Schonfeld Strategic Advisors LLC bought a new stake in Axon Enterprise during the third quarter valued at about $266,000. Diversified Trust Co grew its position in shares of Axon Enterprise by 30.1% during the fourth quarter. Diversified Trust Co now owns 3,196 shares of the biotechnology company's stock valued at $502,000 after purchasing an additional 740 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Axon Enterprise by 36.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 674 shares of the biotechnology company's stock valued at $106,000 after purchasing an additional 179 shares in the last quarter. Koshinski Asset Management Inc. grew its position in shares of Axon Enterprise by 1,441.4% during the fourth quarter. Koshinski Asset Management Inc. now owns 447 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 418 shares in the last quarter. Finally, Stratos Wealth Partners LTD. grew its position in shares of Axon Enterprise by 7.9% during the fourth quarter. Stratos Wealth Partners LTD. now owns 4,538 shares of the biotechnology company's stock valued at $712,000 after purchasing an additional 331 shares in the last quarter. 72.06% of the stock is currently owned by institutional investors and hedge funds.
Get Axon Enterprise alerts:Shares of NASDAQ AXON opened at $94.03 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.43 and a quick ratio of 2.18. The company has a market cap of $6.68 billion, a P/E ratio of 180.83 and a beta of 0.61. Axon Enterprise, Inc. has a 1 year low of $82.49 and a 1 year high of $209.00. The firm has a 50-day simple moving average of $94.35 and a two-hundred day simple moving average of $118.84.
Axon Enterprise (NASDAQ:AXON – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. The business had revenue of $256.43 million during the quarter, compared to the consensus estimate of $233.57 million. Axon Enterprise had a net margin of 4.62% and a return on equity of 3.90%. The firm's quarterly revenue was up 31.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.75) earnings per share. As a group, equities research analysts expect that Axon Enterprise, Inc. will post 1.35 EPS for the current year.In other Axon Enterprise news, Director Mark W. Kroll sold 3,159 shares of the firm's stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $102.82, for a total value of $324,808.38. Following the completion of the sale, the director now owns 13,691 shares of the company's stock, valued at $1,407,708.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by company insiders.
AXON has been the subject of a number of research analyst reports. Credit Suisse Group initiated coverage on Axon Enterprise in a research report on Monday, May 9th. They set an "outperform" rating and a $169.00 price objective for the company. Morgan Stanley lowered Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 price objective for the company. in a research report on Monday, May 23rd. Northland Securities cut their price objective on Axon Enterprise from $180.00 to $130.00 in a research report on Thursday, May 12th. JMP Securities reiterated a "buy" rating and issued a $195.00 price target on shares of Axon Enterprise in a research report on Wednesday, June 1st. Finally, Robert W. Baird dropped their price target on Axon Enterprise from $145.00 to $125.00 in a research report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of "Buy" and a consensus target price of $172.89.
Axon Enterprise Company Profile (Get Rating)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- 3 Growth Stocks Trading at Value P/E's
- Capri Holdings Stock Looks Attractive For a Premium Retailer
- The Sell-Off In Kornit Digital May Set Up A 2nd Half Opportunity
- Phreesia Stock is a Healthcare IT Play
- Recession Resistant Grocery Outlet Holding Corp Quietly Sets New High
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.